Trans Sodium Crocetinate (TSC)

DRUG3 trials

Sponsors

Diffusion Pharmaceuticals Inc

Conditions

GBMGlioblastomaGliomaHigh Grade GliomaIntermittent Claudication

Phase 1

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

CompletedNCT00725881

Diffusion Pharmaceuticals IncIntermittent Claudication

Start: 2008-08-31End: 2010-03-31Updated: 2011-07-29

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

TerminatedNCT00826930

Diffusion Pharmaceuticals IncHigh Grade Glioma

Start: 2009-03-31End: 2009-05-31Updated: 2010-08-12

Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

CompletedNCT01465347

Diffusion Pharmaceuticals IncGBM, Glioblastoma, Glioma

Start: 2012-02-29End: 2016-02-29Updated: 2017-07-14

Related Papers

Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme

Journal of neurosurgery2016-05-1342 citations

Use of a novel radio-sensitizer for treatment of GBM.

Journal of Clinical Oncology2015-05-20

Evaluation of trans sodium crocetinate on safety and exercise performance in patients with peripheral artery disease and intermittent claudication.

2011-10-0115 citations